EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 CLADE C OLIGOMERIC ENVELOPE PROTEIN DELIVERED WITH ADVAX DELTA INULIN ADJUVANT BY INTRAMUSCULAR AND INTRAPULMONARY ROUTES

评估 HIV-1 进化枝 C 寡聚包膜蛋白与 ADVAX Delta 菊粉佐剂通过肌内和肺内途径输送的免疫原性和功效

• 批准号: 10910822
• 负责人: RANAJIT PAL
• 金额: $ 0.34万
• 依托单位: ADVANCED BIOSCIENCE LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-14 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10910822
• 关键词: AIDS Vaccines; Adjuvant; Advanced Development; Animals; Award; Clinical; Complement; Contracts; Control Animal; DNA delivery; Development; Dose; Evaluation; Evaluation Studies; Funding; Grant; HIV; HIV vaccine; HIV-1; Immune response; Immunization; Immunize; Immunotherapy; Intramuscular; Intranasal Administration; Inulin; Investigator-Initiated Research; Local Microbicides; Lung immune response; Modality; Mucous Membrane; National Institute of Allergy and Infectious Disease; Prevention; Prevention strategy; Proteins; Research Personnel; Resources; Route; Vaccine Design; Vaccine Research; Vaccines; Vagina; Virus; efficacy evaluation; env Gene Products; immunogenicity; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; programs; simian human immunodeficiency virus; vaccine candidate; vaccine development; vaccine evaluation

The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators. These studies complement NIAID-supported basic vaccine research and vaccine evaluation studies funded through R01 (investigator-initiated research) grants, HIVRAD (HIV Vaccine Research and Design Program) grants, IPCAVD (Integrated Preclinical-Clinical AIDS Vaccine Development) grants, and NHP Consortium awards. The SVEUs also perform studies of candidate vaccines offered by companies or other researchers.

艾滋病毒疫苗和其他预防策略的开发依赖于在临床前研究中使用非人类灵长类动物，以推动有效的艾滋病疫苗候选疫苗的发展，并促进有效的局部局部杀菌剂和其他预防疗法或免疫疗法的开发。 NIAID Simian疫苗评估单位（SVEU）合同应提供非人类灵长类动物资源，主要支持艾滋病疫苗的临床前评估。 SVEUS进行研究，以支持广泛研究者开发的疫苗。这些研究补充了通过R01（研究人员发起的研究）资助的NIAID支持的基本疫苗研究和疫苗评估研究，HIVRAD（HIV疫苗研究与设计计划）Grants，IPCAVD（综合临床前链式辅助疫苗开发）GRANTS和NHP CONCORTIUM ACHADARDS。 SVEU还对公司或其他研究人员提供的候选疫苗进行研究。